作者: Masahiro Yasunaga , Shinji Saijou , Shingo Hanaoka , Takahiro Anzai , Ryo Tsumura
DOI: 10.1101/397844
关键词:
摘要: The present state of therapy for colorectal cancer (CRC) is far from satisfactory, highlighting the need new targets this disease. We identified a (CRC)-specific molecule, TMEM180, predicted eleven-pass transmembrane protein that apparently functions as cation symporter. Our anti-TMEM180 monoclonal antibody (mAb) eradicated SW480 CRC xenografts in mice. TMEM180 promoter region contains ten hypoxia-responsive element consensus sequences; accordingly cells upregulated under low-oxygen conditions. expression was positively correlated with anchorage-independent colony formation and tumourigenesis. TMEM180-positive resided at tumour-stroma interface manifested by αSMA-positive fibroblasts, also known tumour niche. Some clusters adjacent to niche were integrin α6-positive. These data indicate represents possible stem cell marker mAb against could be used antibody-based therapeutic CRC.